SCHEMBL4864133

SCHEMBL4864133

COc1cc(C2=NNC(=O)C2)cc(OC)c1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 4/20 0.52
PDE4A P27815 2/20 0.52
PDE4C Q08493 2/20 0.52
PDE4D Q08499 2/20 0.52
PDE3B Q13370 2/20 0.52
PDE3A Q14432 2/20 0.52
AXL P30530 1/20 0.49
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 3/20 0.44
GLA P06280 1/20 0.44
HSD17B10 Q99714 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP2C19 P33261 1/20 0.42
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11002952 0.86 PDE3A (0.71) PDE4BPDE4APDE4CPDE4DPDE3B
SCHEMBL3775165 0.83 PDE4B (0.76) PDE4BPDE4APDE4CPDE4DPDE3B
SCHEMBL7260323 0.75 CRBN (0.48) PDE4BPDE4APDE4CPDE4DPDE3B
SCHEMBL5560822 0.73 AXL (0.61) PDE4BPDE4APDE4CPDE4DPDE3B
SCHEMBL4865753 0.71 PDE4B (0.55) PDE4BPDE4APDE4CPDE4DPDE3B
SCHEMBL2644154 0.71 GSTP1 (0.51) PDE4BPDE4APDE4CPDE4DPDE3B
SCHEMBL12847195 0.70 AXL (0.56) PDE4BPDE4APDE4CPDE4DPDE3B
SCHEMBL764744 0.70 AXL (0.56) PDE4BPDE4APDE4CPDE4DPDE3B
SCHEMBL10958746 0.69 PDE4B (0.50) PDE4BPDE4APDE4CPDE4DPDE3B
SCHEMBL6935016 0.69 PDE4B (1.00) PDE4BPDE4APDE4CPDE4DPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7452873-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-18 US disclosed
US-7452873-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-18 US disclosed
US-7452873-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-18 US disclosed
US-20050222237-A1 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2005-10-06 US disclosed
US-6916798-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-07-12 US disclosed
US-20040024040-A1 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-02-05 US disclosed
WO-2003011287-A1 PYRAZOLON DERIVATIVES AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024040-A1 Inhibitors of GSK-3 and uses thereof GSK3B, AURKC, GSK3A PDE4B 3094/4885PDE4A 2901/4885PDE4C 2858/4885
US-20050222237-A1 Inhibitors of GSK-3 and uses thereof GSK3B, AURKC, GSK3A PDE4B 3094/4885PDE4A 2901/4885PDE4C 2858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.